Epidermolysis Bullosa Market Expected to rise, 2034 | Amryt Pharma, Abeona Therapeutics, Castle Creek Pharmaceuticals, RegeneRx, Krystal Biotech, Fibrocell Technologies, RHEACELL GmbH, Holostem Terapi

The Epidermolysis Bullosa market growth is driven by factors like increase in the prevalence of Epidermolysis Bullosa, investments in research and development, entry of emerging therapies during the study period 2020-2034.
The Epidermolysis Bullosa market report [https://www.delveinsight.com/report-store/epidermolysis-bullosa-market?utm_source=blog&utm_medium=promotion&utm_campaign=kpr] also offers comprehensive insights into the Epidermolysis Bullosa market size, share, Epidermolysis Bullosa epidemiology, emerging therapies, market drivers and barriers, ongoing clinical trials, key collaboration in the space, market uptake by key therapies and companies actively pushing Epidermolysis Bullosa market size growth forward.

Some of the key highlights from the Epidermolysis Bullosa Market Insights Report:

*
Several key pharmaceutical companies, including Amryt Pharma, Abeona Therapeutics, Castle Creek Pharmaceuticals, RegeneRx, Krystal Biotech, Fibrocell Technologies, RHEACELL GmbH, Holostem Terapie Avanzate, StemRim, Shionogi, Phoenix Tissue Repair (BridgeBio Pharma, Inc), Menlo Therapeutics, JCR Pharmaceuticals, Amicus Therapeutics, and others, are developing novel products to improve the Epidermolysis Bullosa treatment outlook.

*
In September 2024, a small real-world study showed that Janus kinase (JAK) inhibitors, such as upadacitinib and baricitinib, were more effective than dupilumab in reducing itching and skin lesions in individuals with epidermolysis bullosa pruriginosa (EBP). Among five patients treated with dupilumab, only two experienced a 50% reduction in itching, and none achieved complete relief. In contrast, all five patients treated with JAK inhibitors reported full relief from itching.

*
In December 2023, the FDA approved the use of Filsuvez, a topical gel containing birch triterpenes from Chiesi Global Rare Diseases, for treating partial thickness wounds in patients with junctional and dystrophic epidermolysis bullosa (EB). This approval marks Filsuvez as the only FDA-approved treatment for junctional EB. The decision was based on results from the phase 3 EASE trial, which involved 223 participants across 58 sites in 28 countries, including a three-month randomized controlled phase and a 24-month open-label phase.

*
In 2023, the Epidermolysis Bullosa (EB) market was largest in the US, with a market size of approximately USD 1,300 million, and it is expected to grow further by 2034. Epidermolysis Bullosa simplex (EBS) is the least severe form, with many individuals experiencing improvements as they age, while recessive dystrophic Epidermolysis Bullosa is considered the most severe type. In 2023, over 30% of EB cases were attributed to dystrophic EB, while only 5% were linked to junctional EB.

*
Currently, there are limited effective treatments for EB, and management primarily focuses on supportive care, including wound care, pain and itch management, infection control, nutritional support, and treating complications. Stem cell-based therapies, particularly ABCB5+ mesenchymal stromal cells (MSCs), are gaining attention due to their immunomodulatory and anti-inflammatory properties, showing promise for treating chronic inflammatory conditions like EB.

*
Japan is leading in cell therapy development, having approved the first cell therapy for EB, JACE (human epidermal cell sheet), in December 2018. There is also significant competition in gene therapy development for EB, with Krystal leading by securing FDA approval for VYJUVEK, effective for both recessive and dominant forms of the disease. Abeona's EB-101, a similar gene therapy, also shows promising results. Although Krystal is a year ahead in development, both therapies are vying for market share.

*
Despite these advancements, there remains a significant unmet need for EB therapies, highlighting the importance of continued research and development to improve treatment options and the quality of life for EB patients globally.

*
As per DelveInsight analysis, the Epidermolysis Bullosa market is anticipated to witness growth at a considerable CAGR

Strategise your business goals by understanding market dynamics @ Epidermolysis Bullosa Market Landscape [https://www.delveinsight.com/sample-request/epidermolysis-bullosa-market?utm_source=blog&utm_medium=promotion&utm_campaign=kpr]

Epidermolysis Bullosa Overview

Epidermolysis Bullosa (EB) is a genetic skin disorder marked by fragile skin that blisters easily due to minimal friction or trauma. It is caused by mutations in genes that affect skin proteins essential for structural integrity. The severity of EB varies, from mild cases to life-threatening forms, depending on the subtype. The patient journey typically begins with symptoms like frequent blistering and slow wound healing, prompting caregivers to seek medical attention. Diagnosis is confirmed through skin biopsy and genetic testing to classify the subtype. Following diagnosis, a multidisciplinary team, including dermatologists, wound care specialists, nutritionists, and physiotherapists, develops a treatment plan. Emotional support is also important to help patients cope with the condition. Long-term care and regular follow-ups are essential to monitor skin health and prevent complications. Early diagnosis plays a key role in improving the patient's quality of life.

Do you know the treatment paradigms for different countries? Download our Epidermolysis Bullosa Market Sample Report [https://www.delveinsight.com/report-store/epidermolysis-bullosa-market?utm_source=blog&utm_medium=promotion&utm_campaign=kpr]

Epidermolysis Bullosa Epidemiology Insights

*
In 2023, the United States had the highest prevalence of Epidermolysis Bullosa, making up approximately 65% of the total cases across the 7MM. Meanwhile, the EU4 countries and the UK accounted for around 30%, and Japan represented about 5% of the total prevalence.

*
Within the EU4 and UK regions, the United Kingdom had the highest number of cases, followed by Germany, while Spain had the fewest cases in 2023.

Epidermolysis Bullosa Epidemiology Segmentation

DelveInsight's Epidermolysis Bullosa market report is prepared on the basis of epidemiology model. It offers comprehensive insights to the Epidermolysis Bullosa historical patient pools and forecasted Epidermolysis Bullosa patients. The report provides in-depth data of various subtypes and for the same epidemiology is segmented further. The Epidermolysis Bullosa Market report proffers epidemiological analysis for the study period 2020-34 in the 7MM segmented into:

*
Epidermolysis Bullosa Prevalence

*
Age-Specific Epidermolysis Bullosa Prevalence

*
Gender-Specific Epidermolysis Bullosa Prevalence

*
Diagnosed and Treatable Cases of Epidermolysis Bullosa

Visit for more @ Epidermolysis Bullosa Epidemiological Insights [https://www.delveinsight.com/sample-request/epidermolysis-bullosa-market?utm_source=blog&utm_medium=promotion&utm_campaign=kpr]

Epidermolysis Bullosa Market Insights

Ongoing research into Epidermolysis Bullosa (EB) treatments includes various approaches like gene therapies, cell-based therapies, recombinant protein therapies, and small molecule treatments. Gene therapies, especially VYJUVEK, the first FDA-approved topical gene therapy, are progressing significantly. Other contenders, including Abeona and Castle Creek Biosciences, also aim to introduce COL7A1 into the body.

VYJUVEK uses herpes simplex virus type 1 (HSV-1) as a gene therapy vector, which doesn't integrate into the host's genome, reducing the risk of cancer. JACE, approved in 2018, was the first cell therapy approved for EB. Additionally, stem cell therapies, particularly those using ABCB5+ mesenchymal stromal cells, show promise due to their immune-modulatory properties, aiding chronic wound healing. Other cell-based treatments, such as ISN001 from Ishin Pharma and ALLO-RV-LAMB3-transduced epidermal stem cells from Holostem Terapie Avanzate, are also in development.

Epidermolysis Bullosa Marketed Drugs

*
VYJUVEK (beremagene geperpavec): Krystal Biotech

*
FILSUVEZ (oleogel-S10): Chiesi Farmaceutici

Epidermolysis Bullosa Emerging Drugs

*
EB-101: Abeona Therapeutics

*
D-Fi (dabocemagene autoficel): Castle Creek Biosciences

Epidermolysis Bullosa Key Companies

*
Amryt Pharma, Abeona Therapeutics, Castle Creek Pharmaceuticals, RegeneRx, Krystal Biotech, Fibrocell Technologies, RHEACELL GmbH, Holostem Terapie Avanzate, StemRim, Shionogi, Phoenix Tissue Repair (BridgeBio Pharma, Inc), Menlo Therapeutics, JCR Pharmaceuticals, Amicus Therapeutics, and others

For more information, visit Epidermolysis Bullosa Market Analysis, Patient Pool, and Emerging Therapies [https://www.delveinsight.com/report-store/epidermolysis-bullosa-market?utm_source=blog&utm_medium=promotion&utm_campaign=kpr]

Scope of the Epidermolysis Bullosa Market Report:

*
11 Years Forecast

*
7MM Coverage

*
Descriptive overview of Epidermolysis Bullosa, causes, signs and symptoms, diagnosis, treatment

*
Comprehensive insight into Epidermolysis Bullosa epidemiology in the 7MM

*
Epidermolysis Bullosa marketed and emerging therapies

*
Epidermolysis Bullosa companies

*
Epidermolysis Bullosa market drivers and barriers

Table of Contents:

1 Epidermolysis Bullosa Market Key Comprehensive Insights

2 Epidermolysis Bullosa Market Report Introduction

3 Competitive Intelligence Analysis for Epidermolysis Bullosa

4 Epidermolysis Bullosa Market Analysis Overview at a Glance

5 Executive Summary of Epidermolysis Bullosa

6 Epidermolysis Bullosa Epidemiology and Market Methodology

7 Epidermolysis Bullosa Epidemiology and Patient Population

8 Epidermolysis Bullosa Patient Journey

9 Epidermolysis Bullosa Treatment Algorithm, Epidermolysis Bullosa Current Treatment, and Medical Practices

10 Key Endpoints in Epidermolysis Bullosa Clinical Trials

11 Epidermolysis Bullosa Marketed Therapies

12 Epidermolysis Bullosa Emerging Therapies

13 Epidermolysis Bullosa: 7 Major Market Analysis

14 Attribute analysis

15 Access and Reimbursement Overview of Epidermolysis Bullosa

16 Epidermolysis Bullosa Market Key Opinion Leaders Reviews

18 Epidermolysis Bullosa Market Drivers

19 Epidermolysis Bullosa Market Barriers

20 SWOT Analysis

21 Disclaimer

22 DelveInsight Capabilities

23 About DelveInsight

Related Reports:

Epidermolysis Bullosa Epidemiology 2034

DelveInsight's "Epidermolysis Bullosa - Epidemiology Forecast to 2034" report delivers an in-depth understanding of the disease, historical and forecasted Epidermolysis Bullosa epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Epidermolysis Bullosa Pipeline 2024

"Epidermolysis Bullosa Pipeline Insights, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Epidermolysis Bullosa market. A detailed picture of the Epidermolysis Bullosa pipeline landscape is provided, which includes the disease overview and Epidermolysis Bullosa treatment guidelines.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=epidermolysis-bullosa-market-expected-to-rise-2034-amryt-pharma-abeona-therapeutics-castle-creek-pharmaceuticals-regenerx-krystal-biotech-fibrocell-technologies-rheacell-gmbh-holostem-terapi]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.